High-dose chemotherapy followed by infusion of autologous peripheral blood hematopoietic stem cells (HSCs) is a salvage treatment for relapsed patients with nonHodgkin's lymphoma (NHL).
1,2 Mobilization of HSCs from the marrow to the blood is routinely obtained in these patients by means of chemotherapy and G-CSF. However, patients who have previously received multiple lines of chemotherapy have 430% risk of failing to mobilize a sufficient number of CD34 þ cells (41-2 Â 10 6 kg) in the peripheral blood. In the past, these cases could undergo a BM harvest primed with a short course of G-CSF, 3 or could not be transplanted. Recently, AMD 3100 or Plerixafor (Mozobil, Genzyme, Cambridge, MA, USA), a CXCR4 chemokine antagonist, 4 has been approved by the Food and Drug Administration for mobilization of HSCs when combined with G-CSF in lymphoma and myeloma patients. 5 Plerixafor results in the rapid mobilization of hematopoietic stem cells into the peripheral blood by reversibly blocking the binding of SDF-1a, a chemokine stromal cell-derived factor-1a, to its CXC chemokine receptor, CXCR4. 6 Data on the use of plerixafor in stem cell mobilization with chemotherapy in lymphoma patients are very limited. It has been shown, however, that plerixafor does not mobilize lymphoma cells. 7 We present a case at our institution where plerixafor was used after 2 days of an unsuccessful stem cell collection after mobilization with CY and G-CSF.
A 54-year-old male diagnosed with diffuse large B-cell lymphoma presented to our clinic in his second relapse after 8 cycles of R-CHOP 8 and one cycle of R-ICE 9 chemotherapy at another institution. At diagnosis, the patient presented with supradiaphragmatic node enlargement and BM involvement. When he presented at our institution, he only had enlarged lymph nodes in his neck but no detectable disease in the BM. To avoid further cardiotoxicity due to anthracyclines, he was treated with high-dose MTX and cytarabine according to part II of the hyper CVAD scheme. 10 He obtained a PR and consented to receive an autologous hematopoietic SCT as salvage therapy. Approximately 4 weeks after the last chemotherapy, he received CY 4 g/m 2 and was started on filgrastim at 5 mg/kg twice a day subcutaneously. On day 12 after CY, the patient had a WBC count of 24.5 Â 10 9 /l and 14.7/ml CD34 cells in the blood. He underwent a leukapheresis procedure (14 l processed) that obtained 0.59 Â 10 6 CD34 cells/kg. He continued treatment with figrastim and on the following day the WBC increased to 43.3 Â 10 9 /l, but the number of CD34 cells dropped to 10.3 cells/ml (Figure 1) . The second leukapheresis procedure (20 l processed) resulted in 0.80 Â 10 6 CD34 cells/kg. Owing to the declining number of CD34 cells after the second day, we could not anticipate that a third collection would yield the targeted dose of 2 Â 10 6 CD34 cells/kg in the graft. The choice of using plerixafor in an attempt to rescue an insufficient stem cell mobilization was motivated by the urgency of a salvage therapy with an auto-SCT for this patient. This was explained to the patient who consented to the use of plerixafor. Twelve hours before the third leukapheresis, the patient received 0.24 mg/kg of plerixafor subcutaneously and continued filgrastim injections. Before the third HSC collection, his WBC increased to 63.7 Â 10 9 /l and peripheral blood CD34 cells increased to 44.5/ml. The third apheresis procedure obtained an additional 1.77 Â 10 6 CD34 cells/kg (20 l processed) (Figure 1) , and we were then able to transplant the patient (total CD34 cell dose: 3.16 Â 10 6 /kg) 1 week later after conditioning with the BEAM regimen.
10,11 Plerixafor did not affect the level of Hgb. After the second apheresis, before plerixafor, the patient was thrombocytopenic (plt count: 31 Â 10 9 /l) and was transfused. The number of plts after plerixafor was 76 Â 10 9 /l, suggesting that the mobilizing agent did not affect the response to transfusion. No extrahematologic side effects were observed. Post transplant engraftment of neutrophils 
Â 10
9 /l and plts 420 Â 10 9 /l occurred on days 8 and 10, respectively. This is the first reported case of plerixafor being successfully used to rescue a poor mobilization with chemotherapy and G-CSF. At this time, there are no standard guidelines for the upfront use of plerixafor in stem cell mobilization with chemotherapy. However, this case shows its efficacy in the event of poor stem cell mobilization with a declining number of blood CD34 cells.
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